Rongchang Bio-B issued an announcement that the company has completed the Phase II study of Tetarcept for the treatment of myasthenia gravis patients in China and obtained relevant data results.

2025/07/0211:20:34 finance 1766

Rongchang Bio-B (09995.HK) issued an announcement that the company has completed the Phase II study of Tetarcept (RC18, product name: Tetaravis?) in China for the treatment of myastheniagravis (MG) patients and obtained relevant data results.

As of the close of October 28, 2022, Rongchang Bio-B (09995.HK) closed at 46.25 yuan, down 7.5%, with a turnover rate of 1.51%, a trading volume of 2.869 million shares, and a trading volume of of .135 billion yuan. Investment banks mainly rating the stock on buy. In the past 90 days, 8 investment banks gave buy rating , and the target average price in the past 90 days was 72.95. Industrial Securities 's latest research report gave Rongchang Bio-B an increase rating, with a target price of 73.26.

Institutional rating details are shown in the table below:

Rongchang Bio-B issued an announcement that the company has completed the Phase II study of Tetarcept for the treatment of myasthenia gravis patients in China and obtained relevant data results. - DayDayNews

Rongchang Bio-B Hong Kong stock market value is HK$8.768 billion, ranking 13th in the biologics II industry. The main indicators are shown in the table below:

Rongchang Bio-B issued an announcement that the company has completed the Phase II study of Tetarcept for the treatment of myasthenia gravis patients in China and obtained relevant data results. - DayDayNews

or above content is compiled by Securities Star based on public information and has nothing to do with the position of this site. Securities Star strives but does not guarantee the accuracy, completeness, validity, timeliness of all or part of the content of this information (including but not limited to text, video, audio, data and charts). If there are any problems, please contact us. This article is a data compilation and does not constitute any investment advice to you. Investment is risky, so please make prudent decisions.

finance Category Latest News